Screening young syndrome patients for CFTR mutations

Kenneth J. Friedman, Harry Teichtahl, David M. De Kretser, Peter Temple-Smith, Graeme J. Southwick, Lawrence M. Silverman, W. Edward Highsmith, Richard C. Boucher, Michael R. Knowles

Research output: Contribution to journalArticleResearchpeer-review

13 Citations (Scopus)

Abstract

Young syndrome is characterized by obstructive azoospermia associated with chronic sinobronchial disease of an infectious nature, but normal sweat- gland and pancreatic function as well as normal nasal potential differences. Congenital bilateral absence of the vas deferens (CBAVD) in some patients arises from mutations within the cystic fibrosis (CF) transmembrane regulator (CFTR) gene. Because of some similarities between Young syndrome, CF, and CBAVD, we evaluated 13 patients with Young syndrome, including screening for more than 30 different mutations within the CFTR gene. The mean age of the patients was 43 yr (range, 32 to 50 yr), and all were of northern European extraction. The sweat chloride concentration was normal in all patients (mean = 29 mEq/L; range, 8 to 43 mEq/L). Most had intermittent bronchial and sinus infections, but none was chronically colonized with Staphylococcus aureus or Pseudomonas aeruginosa. The FEV1 was normal or only mildly reduced in most patients (mean = 74%; range, 48 to 100% predicted). Of 26 Young syndrome chromosomes, we identified one with the recognized CF mutation ΔF508. The incidence of CFTR mutations (1 in 26) did not differ significantly from the expected carrier frequency in this population. In summary, it is unlikely that the typical Young syndrome patient has a clinical disease associated with CFTR mutation on both alleles.

Original languageEnglish
Pages (from-to)1353-1357
Number of pages5
JournalAmerican Journal of Respiratory and Critical Care Medicine
Volume152
Issue number4 I
DOIs
Publication statusPublished - 1 Jan 1995

Cite this